AstraZeneca will invest $1.5 billion to establish its first end-to-end antibody-drug conjugate (ADC) production facility in Singapore, with support from the Singapore Economic Development Board.
The plant will focus on manufacturing advanced cancer treatments and is expected to be operational by 2029.
The new facility will achieve zero carbon emissions from its first day of operation, highlighting AstraZeneca's commitment to sustainability. The CEO of AstraZeneca is Pascal Soriot.
